x



Share this page.

SOT Council

SOT is governed by a 13-person elected Council with an administrative office in the Washington, DC, area.



Patricia E. Ganey
President
(2017–2018)

Michigan State University

Experience:
Dr. Ganey is professor of Pharmacology and Toxicology at Michigan State University. She is active in training medical and graduate students and in research. Her research focuses on understanding mechanisms by which inflammation modulates sensitivity of the liver to toxic agents and on understanding mechanisms of drug-induced liver injury. She has authored over 120 research publications in the area of toxicology, and her work has been recognized by the Faculty of 1,000. She has served on the editorial board for Toxicological Sciences and is currently on the editorial boards for Toxicology, the Journal of Toxicology and Environmental Health, and the Journal of Pharmacology and Experimental Therapeutics. She has reviewed grant applications for NIH and served as a consultant for the National Toxicology Program Office of the Report on Carcinogens.

In addition to her service to SOT, Dr. Ganey has represented the interests of Toxicology by serving in the presidential chain for the Division of Toxicology of the American Society for Pharmacology and Experimental Therapeutics.

Participation:
Board of Publications, Member, (2017–2018)
Endowment Fund Board, Ex-Officio Member, (2017–2019)
Finance Committee, Member, (2016–2018)
IUTOX Councilors, Member, (2016–2019)
Officers (Council), President, (2017–2018)
Presidential Chain (PC), Member, (2015–2018)


View Patricia E. Ganey's MyPage on ToXchange


Leigh Ann Burns Naas
Vice President
(2017–2018)

Gilead Sciences, Inc

Experience:
Dr. Burns Naas is Vice President of Drug Safety Evaluation at Gilead Sciences, Inc. She was a Therapeutic Area Leader for Infectious Disease, Vaccines, and Oncology at Pfizer in Drug Safety research and Development over the 10 years preceding her move to Gilead. Prior to that, she worked as a product toxicologist in Health, Environmental, and regulatory Affairs at Dow Corning Corporation in Midland, Michigan. Throughout her career, her work has focused on strategic aspects and the design of safety programs to support chemical product development and registration, and to support the clinical development and licensure for small molecules and biotherapeutics, including vaccines. Dr. Burns Naas has been active in both the Society of Toxicology (SOT) and the American College of Toxicology (ACT) serving on several committees both elected and appointed in both, and serves on the Editorial Board for two journals. She has demonstrated a long commitment to promoting advancements in basic and applied toxicology, the impact of science on human and environmental health across multiple scientific organizations and in the literature, and to participating in the training/education of the next generation of toxicologists. Dr. Burns Naas received her doctorate degree in pharmacology and toxicology from the Medical College of Virginia/VCU in 1992 with an emphasis on immunotoxicology.

Participation:
Board of Publications, Council Contact, (2017–2018)
Finance Committee, Member, (2017–2019)
Nominating Committee for Honorary Members, Member, (2017–2018)
Officers (Council), Vice President, (2017–2018)
Scientific Program Committee, Council Contact, Chair, (2017–2018)


View Leigh Ann Burns Naas's MyPage on ToXchange


Ronald N. Hines
Vice President-Elect
(2017–2018)

Research Triangle Park, NC

Experience:
Dr. Ronald N. Hines is the Associate Director for Health at the National Health and Environmental Effects Research Laboratory (NHEERL) in the Office of Research and Development of the US Environmental Protection Agency (US EPA). In this position, he is the scientific lead for the three NHEERL health divisions and their diverse research portfolio, as well as the Research Core Unit. Dr. Hines also cochairs the National Science and Technology Council’s Toxics and Risk Subcommittee and serves as an US EPA liaison to the National Academy of Science Committee on Emerging Science for Environmental Health Decisions.

Dr. Hines began his academic career as a postdoctoral fellow at the University of Vermont College of Medicine (1980–1983). He accepted a position as Assistant Professor, Eppley Institute for Research in Cancer and Allied Diseases and the Department of Biochemistry, University of Nebraska Medical Center in 1983, and was promoted to Associate Professor in 1988. Dr. Hines was recruited to the Wayne State University School of Medicine as Associate Professor of Pharmacology and Pediatrics Associate in 1989 and in 1995, was promoted to Professor of Pharmacology. In 1999, he assumed a position as Professor of Pediatrics and Pharmacology and Toxicology at the Medical College of Wisconsin, where he also served as Associate Director of the Children’s Research Institute of the Children’s Hospital and Health Systems (2005–2012) and Co-Section Chief of Clinical Pharmacology, Pharmacogenetics, and Teratology in the Department of Pediatrics. In addition, Dr. Hines was Adjunct Professor of Biological Sciences at the University of Wisconsin-Milwaukee (2006–2012). Dr. Hines moved to his current position in 2012. Dr. Hines’ administrative experience includes serving as Assistant Program Leader for the Chemical Carcinogenesis Program at the Myer L. Prentis Comprehensive Cancer Center of Metropolitan Detroit from 1990–1995. Dr. Hines served as a member of the Clinical Pharmacology Training Faculty at Wayne State University and Children’s Hospital of Michigan for seven years (1992–1999). In 1994, he worked as a director for the Regulation of Gene Expression Research Core at the NIEHS-sponsored Environmental Health Sciences Center for Molecular and Cellular Toxicology with Human Applications at Wayne State University from 1994–1997 and from 1997 through 1999, as the deputy director of this center. When recruited to the Medical College of Wisconsin in 1999, he cofounded and served as codirector of the Birth Defects Research Center, Children’s Hospital of Wisconsin and then became the co-chief of the clinical pharmacology, pharmacogenetics and teratology section within the Department of Pediatrics at the Medical College of Wisconsin in 2003. In addition, Dr. Hines served as an associate director of the Children’s Research Institute at the Children’s Hospital and Health Systems from 2005 to 2012; and the deputy director of the NIEHS-sponsored Children’s Environmental Health Sciences Core Center, a joint initiative between the University of Wisconsin Milwaukee, the Children’s Research Institute, and Medical College of Wisconsin, from 2009 to 2012.

Dr. Hines has served on numerous editorial boards, including: Toxicology Letters 1993–1995; Drug Metabolism and Disposition 1994–present; Chemical Research in Toxicology 1995–1997; Archives of Biochemistry and Biophysics 1995–2006; Journal of Pharmacology and Experimental Therapeutics 1997–2000; and Chemico-Biological Interactions 1998–2009. He also has served as an associate editor for: Toxicology and Applied Pharmacology 1996–2004; Birth Defects Research (A), Clinical and Molecular Teratology 2003–2006; Journal of Pharmacology and Experimental Therapeutics 2000–2015; Chemico-Biological Interactions 2009–2012; Toxicological Sciences 2012–present; and Current Opinions in Toxicology 2014–present. Dr. Hines’ selected service experience includes: being a member of the NIH’s Division of Research Grants (DRG) Toxicology I Study Section from 1994–1995; a member and Chair for the NIH DRG Alcohol and Toxicology I Study Section from 1996–1999; Chair for the Mechanisms of Toxicity Gordon Research Conference in 2002; a member of the NIEHS/NTP CERHR Expert Panel on Ethylene Glycol and Propylene Glycol from 2002–2003; a member and Chair of the NIEHS/NTP CERHR Expert Panel on Fluoxetine; a member of ILSI Health and Environmental Sciences Institute Board of Trustees from 2002–2012, Vice Chair 2010–2011, and Chair 2012; member of the US EPA’s Food Quality Protection Act (FQPA) Scientific Review Board from 2003–2012; a member of the US FDA/NCTR Scientific Advisory Board from 2009â–2012; member of the NIEHS EHS Review Committee 2010, and Chair from 2011–2012. Dr. Hines has also received the following honors and awards: NRSA predoctoral fellowship 1977–1980; Danish Cancer Society Travel and Visiting Professorship Award 1987; Wayne State University Board of Governors Distinguished Faculty Fellow Award 1998–2000; Society of Toxicology AstraZeneca Traveling Lectureship 2001; March of Dimes Leadership Award in Research 2005; elected fellow of the Academy of Toxicological Sciences 2007; US EPA/ORD Bronze award for commendable service, Children’s Environmental Health Roadmap; and US EPA/ORD Bronze award for commendable service, Human Research Protection Team.

Dr. Hines has more than 140 publications focused on mechanisms whereby exposures to environmental toxicants or drugs alter gene regulation and the genetic basis for interindividual differences in response to exposures. During the last 13 years of his academic career, his research turned to elucidating how and through what mechanisms the enzymes involved in toxicant and drug disposition change during early life stages and the interaction of genetic variation with this normal developmental process. The impact of this body of work has resulted in Dr. Hines having an h-index of 42 and numerous invitations to present his research at both national and international meetings.

Participation:
Endowment Fund Board, Member, (2016–2018)
FASEB SOT Representatives, FASEB Science Research Conferences Advisory Comm, (2017–2020)
ICT Organizing Committee, Member, (2013–2019)
IUTOX Councilors, Member, (2016–2019)
Nominating Committee, Chair, (2017–2018)
Nominating Committee for Honorary Members, Member, (2017–2018)


View Ronald N. Hines's MyPage on ToXchange


Ruth A. Roberts
Secretary
(2016–2018)

Apconix

Experience:
Dr. Roberts is codirector and cofounder of Apconix, an integrated toxicology and ion channel company and is also adjunct professor at the University of Birmingham, United Kingdom. Before this she was global head of Regulatory Safety at AstraZeneca. She was President of EUROTOX (2012–2014), a past board member and current fellow of the Academy of Toxicological Sciences (ATS), Past President and Life Fellow of the British Toxicology Society (FBTS), a EUROTOX-Registered Toxicologist (ERT), a fellow of the Royal Society of Biology (FRSB) and a fellow of the Royal College of Pathologists (FRCPath). She chaired the 2011 Gordon Conference Cellular and Molecular Mechanisms of Toxicity and past chair (2014–2015) of the ILSI HESI Emerging Issues Committee. She has more than 20 years experience working in the forefront of international research and regulatory toxicology across pharmaceutical, agrochemical, and industrial chemical fields. Dr. Roberts is widely recognized for her expertise in cancer biology, apoptosis, preclinical strategies, and drug development. With more than 130 publications in peer-reviewed journals, Dr. Roberts received the SOT achievement award in 2002 and the EUROTOX Bo Holmstedt Award in 2008 for outstanding scientific contributions to drug and chemical safety.

Participation:
Career Resource and Development Committee, Council Contact, (2015–2018)
Contemporary Concepts in Toxicology Conferences Committee, Council Contact, (2016–2018)
Historian, Member, (2017–2018)
Officers (Council), Secretary, (2016–2018)
ToxSci Associate Editors, ToxSci Associate Editor, (2017–2020)


View Ruth A. Roberts's MyPage on ToXchange


Laurie Couture Haws
Secretary-Elect
(2017–2019)

ToxStrategies, Inc.

Experience:
Dr. Laurie Couture Haws has been an active SOT member for 25 years and, during that time, has served in a variety of leadership and service positions. She is a Diplomate of the American Board of Toxicology and has more than 26 years of experience in the fields of toxicology and risk assessment. Dr. Haws has a diverse background, having worked for both government agencies and the private sector in a variety of capacities. She began her career as a scientist at the National Institute of Environmental Health Sciences, where she worked while pursuing her doctorate. Dr. Haws then spent more than a decade as a regulatory toxicologist with the Texas Commission on Environmental Quality (TCEQ), where she served as a manager in the Toxicology Division. During her tenure with the TCEQ, Dr. Haws was committed to expanding the role and prominence of toxicology within the Commission and was instrumental in growing the group from 3 to more than 30 toxicologists. Dr. Haws has spent the remainder of her career as a consultant in the private sector and is a founder of ToxStrategies, Inc., where she serves as a Managing Principal Scientist and Vice President. During the course of her career, Dr. Haws has worked with federal, state, and local government agencies, industry, trade associations, legislative representatives, the media, and the general public on matters related to the safety of chemicals encountered in our daily lives. She has substantial experience evaluating potential human health risks associated with exposures to a wide variety of chemicals present as additives, ingredients, or contaminants in foods, consumer and personal care products, pharmaceuticals, medical devices, and environmental media. Dr. Haws is an author on over 47 peer-reviewed publications. In addition, she currently serves on the Board of Directors for the Toxicology Forum and is an active member of several additional professional societies, including ACT, SRA, and RAPS. Dr. Haws has also served on a number of scientific panels, technical workgroups, and advisory committees, including the World Health Organization’s Toxic Equivalency Factor Review Panel. Currently, she is serving on the Exposure and Human Health Committee of the US EPA’s Science Advisory Board.

Participation:
American Association for the Advancement of Science Fellows, AAAS, (1900–1900)
Endowment Fund Board, Member, (2016–2019)


View Laurie Couture Haws's MyPage on ToXchange


Michael Aschner
Treasurer
(2016–2018)

Albert Einstein College of Medicine

Experience:
Dr. Aschner is the Harold and Muriel Block Chair and Professor at Albert Einstein College of Medicine. He has served on numerous national and international toxicology panels (Institute of Medicine, US Environmental Protection Agency, Center for Disease Control), served and chaired the Neurotoxicology and Alcohol (NAL) National Institutes of Health Study Section, and authored approximately 500 peer-reviewed manuscripts and chapters in the area of neurotoxicology. He serves as Editor (NeuroMetals) and Associate Editor (Neurotoxicology; Toxicological Science; Neurochemistry Research; Biology Trace Elements Research) and on several other editorial boards. He is a member of the Society of Toxicology (since 1986), Society for Neuroscience, a Fellow of the Academy of Toxicological Sciences, and a Past President of the International Neurotoxicology Association. In 2011, he was the recipient of the Society of Toxicology Merit Award, and in 2013 he was elected as Fellow of the American Association for the Advancement of Science (AAAS). He presently also serves as President of the International Society of Trace Elements Research in Humans. Dr. Aschner directed several large research programs including a P30 (center grant in Molecular Toxicology), the MHRP (Manganese Health Research Program, supported by the Department of Defense), and a T32 Training Grant in Molecular Toxicology.

Participation:
Council Subcommittee for Non-SOT Meeting Funding, Council Contact, Chair, (2017–2018)
Council Subcommittee for Non-SOT Meeting Funding, Member, (2016–2019)
Endowment Fund Board, Member, (2017–2020)
Finance Committee, Member, (2016–2019)
Finance Committee, Council Contact, Chair, (2017–2019)
Officers (Council), Treasurer, (2017–2019)
ToxExpo Liaison Working Group, Council Contact, (2017–2018)


View Michael Aschner's MyPage on ToXchange


John B. Morris
Past President
(2017–2018)

University of Connecticut

Experience:
Dr. Morris is a Board of Trustees Distinguished Professor at the University of Connecticut. He has been on the faculty of the Toxicology Program for 32 years and served as the director of the program from 2000–2010. He served as the head of the Pharmaceutical Sciences Department (2002–2010), assistant dean for research (2008–2013) and is currently completing his term as interim dean of the School of Pharmacy at the University. He maintains active research interests in inhalation toxicology and quantitative inhalation risk assessment and has authored approximately 90 papers and book chapters in the field. His research publications have received many awards including Faculty of 1000 recognition for being among the top 2% of publications in biomedical literature for his work on the counter-irritant effects of menthol in cigarette smoke. He served on the editorial boards of Fundamental and Applied Toxicology, Toxicological Sciences, and Inhalation Toxicology and on the TOX-2 and ALTOX-4 Study Sections for NIH. He has served on air pollutant health assessment review panels for the states of Connecticut, Vermont, and Virginia, as well as for the US Environmental Protection Agency, Centers for Disease Control Agency for Toxic Substances and Disease Registry, and the Department of Energy Office of Health and Environmental Research. He currently serves on two National Academy of Sciences panels. He is a Fellow of the Academy of Toxicological Sciences.

Participation:
Audit Committee, Council Contact, (2017–2018)
Endowment Fund Board, Council Contact, (2017–2018)
Endowment Fund Board, Member, (2017–2019)
FASEB SOT Representatives, FASEB Board Representative, (2017–2021)
ICT Organizing Committee, Council Contact, (2017–2018)
IUTOX Councilors, Member, (2016–2019)
Nominating Committee, Council Contact, (2017–2018)
Nominating Committee for Honorary Members, Council Contact, Chair, (2017–2018)
Officers (Council), Past President, (2017–2018)
SOT FDA Colloquium Organizing Committee, Council Contact, (2017–2018)


View John B. Morris's MyPage on ToXchange


Rosonald R. Bell
Councilor
(2015–2018)

Indivior Inc.

Experience:
Dr. Bell received his BS in biology/premedicine from Florida Agriculture and Mechanical University in Tallahassee, Florida in 1981 and his MS and PhD in pharmaceutical sciences with a concentration in pharmacology/toxicology from Florida Agriculture and Mechanical University in 1989 and 1992, respectively. In 1992, Dr. Bell accepted a two-year postdoctoral research position with The Upjohn Company (now Pfizer Inc.) in Kalamazoo, Michigan under the direction of Dr. Gerald J. Kolaja, where he was involved in nephrotoxicity method development and gained a familiarity with nonclinical drug safety assessment. In 1994, following his postdoctoral fellowship, Dr. Bell joined Ciba Pharmaceuticals Corporation (now Novartis Pharmaceuticals Corporation) in Summit, New Jersey as study director and also managed both the general and reproductive toxicology groups. He became certified in general toxicology in 1996, as a diplomate of the American Board of Toxicology. In 1998, Dr. Bell joined GD Searle/Monsanto in Skokie, Illinois and his primary role was as a Discovery and Development Project Team representative on projects in the arthritis and inflammation therapeutic area. In 2003, Dr. Bell accepted an associate research fellow position with Pfizer Inc. Dr. Bell currently serves as both a regulatory strategy lead and a drug safety team lead at Pfizer Inc., Groton, Connecticut, with the primary responsibility for Pre-FIH–LOE oversight of submissions and regulatory strategies. His responsibilities also include the design and implementation of research projects to support nonclinical safety evaluation of therapeutic agents with special emphasis on injectable anti-inflammatory biotherapeutics. His research interest is in heavy induced pulmonary toxicity with an emphasis on uncovering the biochemical and cytological alterations.

Participation:
Contemporary Concepts in Toxicology Conferences Committee, Co-Council Contact, (2017–2018)
Officers (Council), Councilor, (2015–2018)
PDA/GSLC Symposium Planning Working Group, Council Contact, (2016–2018)
PDA/GSLC Symposium Planning Working Group, Member, (2016–2018)
Postdoctoral Assembly Executive Board, Council Contact, (2016–2018)


View Rosonald R. Bell's MyPage on ToXchange


Michael J. Carvan III
Councilor
(2017–2020)

University of Wisconsin-Milwaukee

Experience:
Dr. Michael J. Carvan completed his postdoctoral studies at the University of Cincinnati Department of Environmental Health where he also held his first faculty position. Dr. Carvan is currently a Shaw Professor at the University of Wisconsin-Milwaukee where he conducts research that is focused on gene-environment interactions and identifying pathways that influence sensitivity to environmental chemicals, especially those that cause birth defects or developmental problems, and those that influence persistence into adulthood and future generations. He serves on the editorial board of several toxicology journals, including Toxicological Sciences and Reproductive Toxicology. He currently serves on the Environmental Health Sciences Review Committee for the NIEHS, and served on the two most recent Institute of Medicine committees for Review of the Health Effects in Vietnam Veterans of Exposure to Herbicides.

Participation:
ToxSci Associate Editors, ToxSci Associate Editor, (2017–2020)


View Michael J. Carvan III's MyPage on ToXchange


Anne H. Chappelle
Councilor
(2017–2020)

International Isocyanate Institute

Experience:
After an internship in an industrial toxicology laboratory, Dr. Anne H. Chappelle enrolled in the pharmacology/toxicology PhD program at the Philadelphia College of Pharmacy and Science (now University of the Sciences), focusing on upper respiratory tract/nasal toxicity. The next 19 years were as an industrial-chemical/regulatory toxicologist in the Philadelphia area (Huntsman Polyurethanes, Rohm & Haas, Sunoco). While the chemical dossiers may have varied, the key functions did not: provide expert chemical evaluations incorporating transparent and rigorous scientific principles, and tailored communications for the appropriate audience (consumer, regulator, CEO, worker, etc.). More recently, Dr. Chappelle has used these skills as a consultant (Chappelle Toxicology Consulting, LLC) helping small and medium sized companies interpret the science to meet regulatory requirements, and a Staff Toxicologist (International Isocyanate Institute) providing strategic management and technical expertise in diisocyanate toxicity.

Dr. Chappelle has been involved with the Mid-Atlantic Regional Chapter (MASOT) since graduate school, first serving on the Membership Committee, where she helped lead efforts to maintain the membership database, produce a directory, and develop strategies and tools to recruit members. She served on the MASOT’s Executive Council, as a Student Councilor, Councilor, and Treasurer, supporting efforts to maintain a strong and diverse chapter that could offer diverse programming and networking opportunities maximizing the value of membership.

Participation:


View Anne H. Chappelle's MyPage on ToXchange


Paul M. D. Foster
Councilor
(2016–2019)

National Toxicology Program-NIEHS

Experience:
Dr. Foster is the Chief of the Toxicology Branch within the Division of the National Toxicology program (NTP) headquartered at the National Institute of Environmental Health Sciences (NIEHS) in Research Triangle Park, North Carolina. The Toxicology Branch is responsible for the scientific leadership of the NTP’s cancer and non-cancer toxicology testing Program. Prior to joining NIEHS in 2002, he was the Director of the research program in endocrine, reproductive and developmental toxicology at the CIIT Centers for Health Research (CIIT). He joined CIIT in December 1995 after a 13-year career at Zeneca’s (formerly Imperial Chemical Industries) Central Toxicology Laboratory in Cheshire, England, where he was head of Reproductive and Developmental Toxicology. He was presented with the European Society of Toxicology’s young scientist award in 1988 for his work on testicular toxicity and has been awarded four NIH Merit awards and an EPA Bronze star. Dr. Foster is a Fellow of the Academy of Toxicological Sciences (ATS) and was elected to the Board of Directors in 2014 and currently serves as the Secretary/Treasurer. He serves on the editorial boards of a number of journals and is a former Associate Editor of Toxicological Sciences (1998–2005). Dr. Foster is internationally recognized for his expertise in developmental and reproductive toxicology and endocrine disruption and has served on a number of international and national (including NRC/NAS) committees in these areas of toxicology. He is the author or co-author of more than 130 peer-reviewed publications and book chapters, including 5 of the top 50 most cited papers (3 in the top 10) in Toxicological Sciences and numerous regulatory study reports.

Participation:
Continuing Education Committee, Council Contact, (2016–2018)
Membership Committee, Council Contact, (2016–2018)
Officers (Council), Councilor, (2016–2019)


View Paul M. D. Foster's MyPage on ToXchange


Mary Beth Genter
Councilor
(2016–2019)

University of Cincinnati

Experience:
Dr. Genter is a Professor in the Department of Environmental Health at the University of Cincinnati. She followed her graduate studies in neurotoxicology with a postdoctoral fellowship at the Chemical Industry Institute of Toxicology. Her first academic position was in the Department of Toxicology at North Carolina State University. Her position there included research, teaching, and service as the toxicologist for the North Carolina Cooperative Extension Service. Dr. Genter joined the Department of Environmental Health at the University of Cincinnati in 1999 and is currently a full professor. Her research interests and expertise include extrahepatic biotransformation; olfactory epithelial biology and toxic responses; and intranasal drug delivery.

Participation:
Career Resource and Development Committee, Co-Council Contact, (2017–2018)
Education Committee, Council Contact, (2017–2018)
Education Subcommittee: Graduate Education, Council Contact, (2016–2018)
Education Subcommittee: Undergraduate Education, Council Contact, (2016–2018)
FASEB SOT Representatives, FASEB Pub & Communications Committee Rep, (2017–2020)
Officers (Council), Councilor, (2016–2019)
Undergraduate Consortium Task Force, Council Contact, (2017–2020)


View Mary Beth Genter's MyPage on ToXchange


Tao Wang
Councilor
(2015–2018)

Achaogen, Inc.

Experience:
Dr. Wang brings to the SOT leadership perspectives a broad range of professional experiences including clinical practice in Oncology, academic research as a NIEHS postdoctoral fellow investigating gene regulation, and professional Toxicology practice in the pharmaceutical industry supporting clinical development and licensure for small molecule and biotherapeutics. Dr. Wang is Director of Toxicology at Achaogen, Inc., where she has responsibility for all toxicology functions across early and late stage development programs, including nonclinical safety strategies, operations, resourcing, budget & timelines. Prior to joining Achaogen, Dr. Wang worked at Novartis Pharmaceuticals for more than a decade, leading safety assessment efforts for oncology and infectious disease drug development projects. During her tenure at Novartis, Dr. Wang received multiple awards, recognizing not only her significant achievements above and beyond work requirements, but also her outstanding collaboration on multidisciplinary teams. Dr. Wang has been an active member in both the SOT and American Board of Toxicology (ABT) for many years, serving on several committees both elected and appointed. She also serves on the Editorial Board for International Journal of Toxicology and Toxicology Research and Application. Dr. Wang remains active in the research community, publishing results of her research in peer-reviewed journals. Dr. Wang also teaches in Practical Toxicology course at the University of California at Berkeley as a guest lecturer. She has demonstrated a long-standing commitment to promoting advancements in basic and applied toxicology, and a passion to participate in the training/education of the next generation of toxicologists.

Participation:
Clinician-Scientist Engagement Task Force, Council Contact, (2017–2018)
Committee on Diversity Initiatives, Council Contact, (2017–2018)
Education Committee, Council Contact, (2016–2018)
Education Subcommittee: Graduate Education, Council Contact, (2016–2018)
Education Subcommittee: Undergraduate Education, Council Contact, (2016–2018)
Officers (Council), Councilor, (2015–2018)


View Tao Wang's MyPage on ToXchange


Tonia M. Masson
Executive Director

Experience:
Ms. Masson recently served as the SOT Deputy Director will continue to serve SOT Council in shaping the strategy for fostering collaboration opportunities with other scientific societies and to fulfill SOT's mission.

Ms. Masson has been with AIM, our management company since 1999 and is a founding managing partner. She served as the Executive Director for the Environmental Mutagenesis and Genomics Society, the Teratology Society, and the Toxicology Forum.

Ms. Masson is a member of the American Society of Association Executives (ASAE).

Participation:
Contemporary Concepts in Toxicology Conferences Committee, Staff Liaison, (2008–2019)
Scientific Liaison Coalition, Staff Liaison, (2015–2019)


View Tonia M. Masson's MyPage on ToXchange